Destiny Pharma Lancet Report
Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Important Lancet report highlights growing threat of Antimicrobial Resistance with over one million deaths per year
Destiny Pharma’s XF platform is delivering effective drug candidates that also address the threat of AMR
Brighton, United Kingdom, 21 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today notes the publication of a major Lancet study highlighting that over one million deaths occurred in 2019 due to bacterial Antimicrobial Resistance (AMR) and that AMR is one of the leading causes of death across the world. The report also notes the importance of infection prevention in mitigating AMR and names Staphylococcus aureus as one of the six leading lethal pathogens.
